- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07780188
Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) (Beef+)
19. srpna 2026 aktualizováno: Heidi Vanden Brink, Texas A&M University
Effect of Increasing Lean Beef Intake as Part of a Healthy Meal Plan on Glycemic Control in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)
This pilot randomized controlled study will plan to enroll 36 adolescent females with Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) to evaluate the effectiveness and feasibility of a tailored dietary intervention which will be termed "Beef+", that will emphasize the incorporation of unprocessed, lean beef (<10% fat) as part of a healthy meal plan to improve glycemic control, diet quality, and health-related quality of life
Přehled studie
Postavení
Nábor
Podmínky
Intervence / Léčba
Detailní popis
Youth-onset Type 2 Diabetes (T2D) is a chronic disease characterized by accelerated beta cell decline and severe insulin resistance (IR).
Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a well-established independent risk factor for youth-onset T2D.
A first line of treatment for PCOS is lifestyle intervention; however, there is a paucity of evidence evaluating the effectiveness of nutritional strategies in adolescents with PCOS.
The overarching goal of the pilot study, termed Beef+, is to replace intake of high fat, processed red meat products with lean beef ("Beef") prepared as part of healthy meals that target increased vegetable and complex carbohydrate intake per the Dietary Guidelines for Americans ("+") and reducing intake of saturated fat, sodium, and added sugar.
We will test the hypothesis that incorporating lean beef as part of a healthy meal plan will improve glucoregulation (Aim 1), enhance overall diet quality and satiety (Aim 2), and be a feasible and acceptable dietary intervention strategy that improves participant and household health-related quality of life (Aim 3).
Typ studie
Intervenční
Zápis (Odhadovaný)
36
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní kontakt
- Jméno: Heidi K Vanden Brink, PhD, MSc, RDMS
- Telefonní číslo: 979-321-7073
- E-mail: heidi.vandenbrink@ag.tamu.edu
Studijní místa
-
-
Texas
-
College Station, Texas, Spojené státy, 77843
- Nábor
- Texas A&M AgriLife
-
Kontakt:
- Heidi Vanden Brink
- Telefonní číslo: 979--321-7073
- E-mail: heidi.vandenbrink@ag.tamu.edu
-
Dílčí vyšetřovatel:
- Michele Garant, DO
-
Dílčí vyšetřovatel:
- Seung-Yeon "Shawn" Ha, PhD
-
Dílčí vyšetřovatel:
- Lilian Ademu, PhD
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
Přijímá zdravé dobrovolníky
Ne
Popis
Inclusion Criteria:
- Female Adolescent
- 11-17 years old
- Suspected or confirmed diagnosis of PCOS
- ≥1-year post-menarche
- BMI ≥85th percentile for age/height
- Able to read and speak English
Exclusion Criteria:
- Medications affecting glucoregulation, metabolic health, and/or appetite (e.g., metformin, GLP-1)
- Unable or unwilling to eat beef
- Pregnant or planning pregnancy during study
- HbA1c ≥6.5%
- Unwilling or unable to complete study procedures
- Conditions affecting ability to complete study procedures or the intervention such as gastrointestinal diseases or syndromes, bleeding disorders, ongoing or unresolved eating disorder)
- Conditions affecting reproductive function other than PCOS
- Conditions that may interfere with continuous glucose monitor (CGM) application or use, including dermatological conditions such as eczema or allergies/reactions to medical adhesives
Conditional Exclusion Criteria:
- Current use of hormonal contraceptives if in the suspected PCOS group (allowable if current for at least the previous 3 months with physician-confirmed PCOS)
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Žádný zásah: Control/Usual Lifestyle with optional Delayed Intervention
Participants randomized to usual lifestyle will continue with their usual lifestyle/ diet.
Participants will undergo all scheduled study procedures.
Upon completion of the 12-week of usual lifestyle, participants randomized to the delayed onset control group will be offered one month of the dietary intervention.
The delayed intervention is optional.
|
|
|
Experimentální: Beef+
|
Adolescents will be instructed to consume a minimum of 1 (3oz) serving per day of cooked unprocessed, lean (<10% fat) beef (21 oz/week) for 12 weeks.
To facilitate adoption, the intervention will be offered at the household level, but it is not a requirement.
The intervention is a multi-modal behavior change intervention with three overarching components: modifying beef intake, consuming beef in healthy meals, and the research team purchasing the beef needed for the intervention.
To facilitate adoption of lean beef as part of a healthy diet, a study RDN will meet with the participant and at least one representative parent/guardian at bi-weekly check-ins to provide tailored dietary support and develop an implementation plan.
A financial supplement of $100/month will be provided offset grocery costs.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in HbA1c
Časové okno: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
HbA1c measured as point of care using A1CNow+ point-of-care analyzer, HbA1c will also serve as a safety endpoint.
|
Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in 2-hour Fasting Glucose
Časové okno: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from a 75g oral glucose tolerance test (OGTT) as a measure of glycemic variability
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Dropout rate
Časové okno: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Drop-out and the reason for drop-out will be recorded, and in both the intervention and usual lifestyle groups will be reported.
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Matsuda Index
Časové okno: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from a 75g oral glucose tolerance test (OGTT), measure of insulin sensitivity
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Insulinogenic Index
Časové okno: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from the 75g oral glucose tolerance test (OGTT), measure of insulin sensitivity
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Disposition Index
Časové okno: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from a 75g oral glucose tolerance test (OGTT), measure of insulin sensitivity
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in 2nd Phase Insulin Release
Časové okno: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from a 75g oral glucose tolerance test (OGTT), as a measure of insulin sensitivity
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Time in Range
Časové okno: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
Derived from blinded Continuous Glucose Monitor (CGM) wear, a measure of glycemic variability
|
Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Continuous Overall Net Glycemic Action (CONGA)
Časové okno: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
Derived from blinded Continuous Glucose Monitor (CGM) wear, as a metric of glycemic variability
|
Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Glycemic Risk Assessment in Diabetes Education (GRADE)
Časové okno: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
Derived from blinded Continuous Glucose Monitor (CGM) wear, measure of glycemic variability
|
Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Diet Quality - Dietary Recalls
Časové okno: Baseline and Week 14
|
This will be assessed from 24-hour diet recalls and evaluated via Healthy Eating Index (HEI).
|
Baseline and Week 14
|
|
Change in Diet Quality - Skin Carotenoids
Časové okno: Baseline and Week 14
|
Skin carotenoids will be measured through the Veggie Meter ®, which uses reflection spectroscopy to estimate skin carotenoid levels.
Three scans will be taken on your non-dominant ring finger.
After each scan, a dial gauge and a score will appear on the screen.
A final score, calculated as the average of the three scans, will range from 0 to 800.
Higher scores indicate greater fruit and vegetable intake.
|
Baseline and Week 14
|
|
Change in Perceived Hunger
Časové okno: Baseline and Week 14
|
This will be measured through an Appetite/Satiety Questionnaire adapted from commonly used appetite assessment methods and previously applied in dietary intervention research.
Participants will report their general appetite and satiety experiences using six items assessing hunger frequency, strength of hunger before meals, fullness after eating, desire to eat when food is available, thoughts about food, and satisfaction after eating.
Responses are recorded using a 100-mm visual analogue scale implemented as a 0-100 slider (0 = lowest intensity or frequency; 100 = highest intensity or frequency).
Participants will be instructed to move the slider to reflect how strongly each statement describes their typical experience.
Data collected will be used to evaluate changes in perceived hunger and fullness throughout the intervention.
|
Baseline and Week 14
|
|
Change in incident Pre and Type 2 Diabetes
Časové okno: Baseline, Week 6, and Week 12 of Intervention or Usual Lifestyle
|
Type 2 Diabetes is defined as HbA1c >6.5%.
|
Baseline, Week 6, and Week 12 of Intervention or Usual Lifestyle
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Compliance- Lean beef intake by self-report
Časové okno: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Intake of lean beef, assessed via 24-hour diet recalls
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Compliance - Daily Survey
Časové okno: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Intake of lean beef, assessed through daily logs of beef intake by providing portion sized objects that align with serving sizes and ask participants to take photos of their meals with the portion estimator, to ensure that both the meal planning is followed and portion sizes are met.
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Compliance - Blood Biomarkers
Časové okno: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Serum hemoglobin will also be assessed as a metric of compliance.
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Participants' Quality of Life
Časové okno: Baseline and and Week 14
|
This will be measured through the Pediatric Quality of Life (PedsQL) questionnaire.
It includes 23 questions and is scored by reverse-scoring items and linearly transforming them to a 0-100 scale.
Higher scores mean better health-related quality of life.
|
Baseline and and Week 14
|
|
Household Quality of Life
Časové okno: Baseline and Week 14
|
This will be measured through the Adapted version of the Family Impact Module of the Pediatric Quality of Life (PedsQL).
This questionnaire includes 36 questions and includes a 5-point Likert scale (0 to 4), reverse-scored and linearly transformed to a 0-100 scale.
Higher scores show better parent health-related quality of life and family functioning with less negative impact.
|
Baseline and Week 14
|
|
Exploratory Analysis - Lean Beef
Časové okno: Baseline and Week 14
|
An exploratory analysis will reveal whether lean beef was directly associated with any change in glycemic outcome over time
|
Baseline and Week 14
|
|
Economic Evaluation of the Intervention (Ancillary Study, Optional)
Časové okno: Baseline and Week 14
|
An exploratory economic evaluation will estimate household food-related costs associated with participation in the intervention as an ancillary study.
Parents or legal guardians will be invited to record and provide receipts for costs related to groceries or food purchased for at-home meal preparation, as well as for meals purchased outside the home, including at restaurants and fast-food venues
|
Baseline and Week 14
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Heidi K Vanden Brink, PhD, MSc, RDMS, Texas A&M University
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Odhadovaný)
1. září 2026
Primární dokončení (Odhadovaný)
30. dubna 2028
Dokončení studie (Odhadovaný)
30. dubna 2028
Termíny zápisu do studia
První předloženo
7. srpna 2026
První předloženo, které splnilo kritéria kontroly kvality
19. srpna 2026
První zveřejněno (Aktuální)
21. srpna 2026
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
21. srpna 2026
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
19. srpna 2026
Naposledy ověřeno
1. srpna 2026
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění genitálií
- Onemocnění endokrinního systému
- Patologické procesy
- Poruchy výživy
- Novotvary
- Mužská urogenitální onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Nadměrná výživa
- Tělesná hmotnost
- Onemocnění pohlavních orgánů, ženy
- Onemocnění vaječníků
- Adnexální onemocnění
- Gonadální poruchy
- Kožní choroby
- Vrozené vady
- Nemoci vlasů
- Ovariální cysty
- Cysty
- Poruchy pohlavního vývoje
- Urogenitální abnormality
- Virilismus
- 46, XX Poruchy vývoje pohlaví
- Adrenogenitální syndrom
- Vrozené, dědičné a neonatální nemoci a abnormality
- Patologické stavy, příznaky a symptomy
- Nutriční a metabolické nemoci
- Onemocnění kůže a pojivové tkáně
- Příznaky a symptomy
- Nadváha
- Syndrom polycystických vaječníků
- Hirsutismus
- Poruchy menstruace
- Hyperandrogenismus
- Jídlo
- Strava, jídlo a výživa
- Fyziologické jevy
- Jídlo a nápoje
- Maso
- Červené maso
Další identifikační čísla studie
- IRB#STUDY2026-0483
- #2681 (Jiný identifikátor: National Cattlemen's Beef Association, a contractor to the Beef Checkoff)
- Lab Research Funds (Jiný identifikátor: Texas A&M AgriLife)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
NE
Popis plánu IPD
Individual participant data is not anticipated to be shared on a publicly available database because this is not a federally funded study and given the nature of the data collected and vulnerable population.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .